Exhibit 99.1
Catalyst Pharmaceuticals Appoints Jeffrey Del Carmen as Chief Commercial Officer
-Pete Curry has been Promoted to Vice President of Sales
-Maria Pandolfo has been Promoted to Vice President of Patient Services
CORAL GABLES, Fla., June 23, 2020 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst)(Nasdaq: CPRX), a commercial-stage biopharmaceuticalcompany focused on developing and commercializing innovativetherapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the promotion of Jeffrey Del Carmen to Chief Commercial Officer, effective today. Mr. Del Carmen joined Catalyst in August of 2018 as Senior Vice President of Sales and Marketing. In his new role, Mr. Del Carmen will report to the CEO of Catalyst and will serve on Catalyst’s Executive Leadership Team.
Catalyst also announced that Pete Curry, Sr. has been promoted to Vice President of Sales (from his current position as Catalyst’s National Sales Director) and that Maria Pandolfo has been promoted to Vice President of Patient Services. Both will continue to report to Mr. Del Carmen in his new role as Catalyst’s Chief Commercial Officer.
“Jeff has proven his ability by leading the sales and marketing team that successfully launched Firdapse® for the treatment of adult LEMS patients in the United States,” said Patrick J. McEnany Chairman and CEO of Catalyst. “With Jeff’s leadership and experience, Catalyst is well-positioned for sustained success as we continue to expand access to Firdapse to the LEMS community, as well as prepare for a potential launch of Firdapse for the treatment of patients suffering from anti-MuSK antibody positive myasthenia gravis (“MuSK-MG).”
Mr. McEnany added, “On behalf of the Company, I would like to thank Dan Brennan for his leadership and significant contributions over the past two years and wish him success as he pursues his next opportunity.”
“During the past two years, Catalyst has made tremendous progress in establishing a commercial organization that has rapidly provided access to Firdapse for many LEMS patients across the United States, and I am excited to build on the launch momentum as we continue to bring this important medication to LEMS patients and hopefully to patients who will benefit from the use of Firdapse for the treatment of other rare neuromuscular conditions,” said Jeff Del Carmen.
Mr. Del Carmen has more than 23 years of experience in pharmaceutical sales and product management. Just prior to joining Catalyst, Mr. Del Carmen served as VP of Business Development at Paragon Biosciences, evaluating commercial assets to expand Paragon’s portfolio. Previously, Mr. Del Carmen was Senior Director-Rare Disease Marketing at Marathon Pharmaceuticals. Prior to joining Marathon, Mr. Del Carmen briefly served as Vice President of Sales at Insys Therapeutics. From 2011 to 2016, Mr. Del Carmen was with Lundbeck (US), with the last two years as Movement Disorder-National Sales Director.
